Skip to main content Skip to section navigation Skip to footer
Back to AchieveLifeSciences.com
Achieve Life Sciences, Inc. Investor Relations
  • Investors
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information
ORCA-3 Phase 3 Trial Reports Statistically Significant Topline Efficacy Results in Smoking Cessation
View

Press Releases

News & Events

News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 15, 2022 8:00am EST

Achieve Life Sciences Announces Private Placement of $18.9 Million

Nov 14, 2022 4:05pm EST

Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update

Nov 08, 2022 8:00am EST

Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial

Oct 31, 2022 8:00am EDT

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

Sep 27, 2022 8:00am EDT

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Sep 07, 2022 8:00am EDT

Achieve Life Sciences Announces Participation at Fall Investor Conferences

Aug 11, 2022 4:05pm EDT

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

Jul 28, 2022 8:00am EDT

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

Jul 01, 2022 4:05pm EDT

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Jun 29, 2022 8:00am EDT

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Achieve Life Sciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap